- Home
- LBRDK vs JAZZ Comparison
LBRDK vs JAZZ Comparison
Compare LBRDK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDK
- JAZZ
- Stock Information
- Founded
- LBRDK 2014
- JAZZ 2003
- Country
- LBRDK United States
- JAZZ Ireland
- Employees
- LBRDK N/A
- JAZZ N/A
- Industry
- LBRDK Cable & Other Pay Television Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- LBRDK Telecommunications
- JAZZ Health Care
- Exchange
- LBRDK Nasdaq
- JAZZ Nasdaq
- Market Cap
- LBRDK 8.4B
- JAZZ 8.2B
- IPO Year
- LBRDK N/A
- JAZZ 2007
- Fundamental
- Price
- LBRDK $58.43
- JAZZ $136.05
- Analyst Decision
- LBRDK
- JAZZ Strong Buy
- Analyst Count
- LBRDK 0
- JAZZ 14
- Target Price
- LBRDK N/A
- JAZZ $179.21
- AVG Volume (30 Days)
- LBRDK 1.0M
- JAZZ 653.6K
- Earning Date
- LBRDK 11-05-2025
- JAZZ 11-05-2025
- Dividend Yield
- LBRDK N/A
- JAZZ N/A
- EPS Growth
- LBRDK 36.76
- JAZZ N/A
- EPS
- LBRDK 7.58
- JAZZ N/A
- Revenue
- LBRDK $1,052,000,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- LBRDK $8.37
- JAZZ $5.70
- Revenue Next Year
- LBRDK $2.91
- JAZZ $6.16
- P/E Ratio
- LBRDK $7.70
- JAZZ N/A
- Revenue Growth
- LBRDK 7.24
- JAZZ 4.52
- 52 Week Low
- LBRDK $57.75
- JAZZ $95.49
- 52 Week High
- LBRDK $97.38
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- LBRDK 36.98
- JAZZ 58.74
- Support Level
- LBRDK $59.24
- JAZZ $132.41
- Resistance Level
- LBRDK $62.00
- JAZZ $137.43
- Average True Range (ATR)
- LBRDK 1.95
- JAZZ 3.13
- MACD
- LBRDK -0.38
- JAZZ -0.52
- Stochastic Oscillator
- LBRDK 7.13
- JAZZ 63.50
About LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.